Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lab21 Among First to Offer FDA Approved Companion Diagnostic in the US

Published: Monday, July 16, 2012
Last Updated: Monday, July 16, 2012
Bookmark and Share
CLIA laboratory to provide guidance for the use of Erbitux®.

Lab21 Limited has announced that its CLIA laboratory in Greenville, South Carolina, has been named as one of nine laboratories in the US to offer the first FDA approved companion diagnostic test to provide guidance for the use of Erbitux® (cetuximab).

Recent FDA approval of the Qiagen therascreen KRAS test, allows it to be used to determine whether patients with metastatic colorectal cancer are suitable for treatment with Erbitux.

The test has been routinely used in Europe since 2008 and is the first KRAS assay to secure FDA approval.

The availability of this test gives healthcare providers an FDA approved test which provides fast, consistent and reliable data to determine optimal treatment for colorectal cancer patients who are candidates for EGFR-targeted inhibitor therapy.

Lab21 has been providing a KRAS analysis service using the assay from its CPA Accredited laboratory in Cambridge, UK for both Amgen and Merck Serono since 2008, and has performed in excess of 6000 tests during this time, including patient samples originating in a number of countries in Europe and the Middle East.

Michael Bolick, President of Lab21 Inc., commented: “Lab21 Inc. is delighted to have launched the therascreen KRAS assay as part of our initial portfolio of molecular diagnostic tests. As the only laboratory in Qiagen’s launch group based in the South-eastern region of the US market, Lab21 is well positioned to be the first provider of this valuable service to the regional cancer community.”

Mike Annable, Divisional Director - Clinical Laboratory, added, “Lab21 has significant clinical experience with the therascreen KRAS assay having been one of the first commercial labs to provide this validated assay in the UK. We have been able to leverage this experience during the laboratory validation of the assay for the US market and we are pleased that Erbitux patients can benefit from this experience.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lab21 Partners with Top 10 IVD Player
Agreement to develop, manufacture and distribute new Aspergillus molecular assay.
Wednesday, April 11, 2012
Lab21 Announces Appointment of Industry Expert Fraser Logue
Dr Logue joins Lab21 team as Group Director of Quality, Regulatory Affairs & Operations Excellence.
Tuesday, February 21, 2012
Scientific News
New Tool Could Change How Infectious Diseases Are Diagnosed
Scientists at the University of Utah School of Medicine, ARUP Laboratories, and IDbyDNA, Inc., have developed ultra-fast, meta-genomics analysis software called Taxonomer that dramatically improves the accuracy and speed of pathogen detection.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!